2026· Advances in Pharmacology· Vol 106, pp.
213-251
· 1 citation
Medicine
TL;DR
A review of the biological rationale, delivery engineering, immunological barriers, CAR payload design, early clinical evidence, and future directions of this field focuses on the pharmacological principles that distinguish in vivo from ex vivo approaches and on the transformative potential for indications that lie beyond the current reach of conventional CAR T cell therapy.
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of several hematological malignancies, but its broader application remains constrained by the complexity, cost, and time required for conventional ex vivo manufacturing. In vivo CAR T-cell therapy has emerged as a promising next-generation str...
This review highlights key engineering strategies enabling in vivo CAR T-cell generation, summarizes emerging clinical research and development, and discusses future opportunities for expanding in vivo CAR T-cell therapies as scalable immunotherapy platforms.
Janani Gopalakrishnan, Bhagyashri Rathod, Sachin Puri· International Immunopharmaco...· 0 citations
If in-vivo CAR-T therapy approaches continue to mature, they may offer a more scalable, cost-effective, and accessible alternative to traditional ex vivo CAR-T therapy, though this remains a projected rather than demonstrated benefit.
Lia Bhatia· American Journal of Student...· 0 citations
The intrinsic trade-off between therapeutic durability and biosafety across distinct delivery platforms is discussed, along with the necessity that their clinical translation hinges on systematic optimization of delivery precision, immune compatibility, and expression controllability.
Meifen Luo, Kai Liao, Jinxi Chang et al.· Advances in Materials· 0 citations
Nonviral NPs are poised to redefine CAR therapy by enabling scalable, off-the-shelf immune interventions for cancer, autoimmune, and fibrotic diseases.
Ke Huang, Hao Wang, Tao Zhu et al.· Biomaterials· 1 citation
Although still in its infancy, in vivo genetic engineering shows promise for CAR T cell therapy in a wide range of cancer patients and has the potential to reprogram patients’ immunity in autoimmunity, chronic infections, and regenerative medicine.
Markus Barden, D. Harrer, Hinrich Abken· Expert Opinion on Biological...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
